Who are Iloprost (Ventavis)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epalrestat,Mecobalamin, FLOLAN injection with reformulated diluent, Inhaled Epoprostenol and phenylephrine, Ventavis (Iloprost, BAYQ6256), Treprostinil Injectable Product, ONO-8025 (KRP-197).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iloprost-ventavis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Iloprost (Ventavis) — Competitive Intelligence Brief

Iloprost (Ventavis) (Iloprost (Ventavis)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analog. Area: Cardiovascular.

phase 3 Prostacyclin analog Prostacyclin receptor (IP receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Iloprost (Ventavis) (Iloprost (Ventavis)) — Ludwig-Maximilians - University of Munich. Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Iloprost (Ventavis) TARGET	Iloprost (Ventavis)	Ludwig-Maximilians - University of Munich	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)
Epalrestat,Mecobalamin	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes
FLOLAN injection with reformulated diluent	FLOLAN injection with reformulated diluent	GlaxoSmithKline	marketed	Prostacyclin analog	Prostacyclin receptor (IP receptor)
Inhaled Epoprostenol and phenylephrine	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor
Ventavis (Iloprost, BAYQ6256)	Ventavis (Iloprost, BAYQ6256)	Bayer	phase 3	Prostacyclin analogue	Prostacyclin receptor
Treprostinil Injectable Product	Treprostinil Injectable Product	University of Arizona	phase 3	Prostacyclin analogue	Prostacyclin receptor
ONO-8025 (KRP-197)	ONO-8025 (KRP-197)	Ono Pharmaceutical Co. Ltd	phase 3	Prostacyclin analog / IP receptor agonist	Prostanoid IP receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analog class)

Liquidia Technologies, Inc. · 2 drugs in this class
AOP Orphan Pharmaceuticals AG · 1 drug in this class
Civi Biopharma, Inc. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Lung Biotechnology PBC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iloprost (Ventavis) — Competitive Intelligence Brief. https://druglandscape.com/ci/iloprost-ventavis. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab